Companies Anticipate Increased Availability of Standalone Benefits
Daniel Payne covers the intersection of health policy and Washington, reporting for STAT since 2025 after previous work at POLITICO. Reach him on Signal at danielp.100.
WASHINGTON — The Trump administration’s initiative to enhance the affordability of in vitro fertilization is positively altering expectations and offerings within the fertility community, despite some of the specifics remaining undisclosed and awaiting announcement.
This initiative has sparked optimism for a rise in demand for IVF and fertility services, potential cost reductions for patients, and even the introduction of fresh offerings, as expressed by industry leaders to STAT.
“This is a pivotal moment for our sector,” remarked Tammy Sun, CEO of Carrot, a company specializing in workplace fertility benefits with millions of members. She pointed out that the administration’s focus is “an unprecedented milestone.”
STAT+ Subscriber Exclusive
Already a member? Log in
This article is exclusive for STAT+ subscribers
Unlock this article — along with daily biopharma market analysis — by subscribing to STAT+.
Already have an account? Log in
-
Daniel Payne provides insights on how the health industry and policy environments intertwine. Having joined STAT in 2025 from POLITICO, he can be contacted via Signal at danielp.100.
Suggested Reads
The Readout
The Readout
The Readout
Insurance Insights
Opinion Piece
